ES2567451T3 - Compuestos de oxadiazoantraceno para el tratamiento de diabetes - Google Patents
Compuestos de oxadiazoantraceno para el tratamiento de diabetes Download PDFInfo
- Publication number
- ES2567451T3 ES2567451T3 ES09718287T ES09718287T ES2567451T3 ES 2567451 T3 ES2567451 T3 ES 2567451T3 ES 09718287 T ES09718287 T ES 09718287T ES 09718287 T ES09718287 T ES 09718287T ES 2567451 T3 ES2567451 T3 ES 2567451T3
- Authority
- ES
- Spain
- Prior art keywords
- fused
- group
- aryl
- alkylene
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004419 alkynylene group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 abstract 1
- 125000005215 cycloalkylheteroaryl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3459908P | 2008-03-07 | 2008-03-07 | |
| US34599 | 2008-03-07 | ||
| PCT/US2009/036333 WO2009111700A2 (en) | 2008-03-07 | 2009-03-06 | Oxadiazoanthracene compounds for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2567451T3 true ES2567451T3 (es) | 2016-04-22 |
Family
ID=41056666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09718287T Active ES2567451T3 (es) | 2008-03-07 | 2009-03-06 | Compuestos de oxadiazoantraceno para el tratamiento de diabetes |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7727983B2 (enExample) |
| EP (1) | EP2262364B1 (enExample) |
| JP (1) | JP5382952B2 (enExample) |
| KR (1) | KR101616737B1 (enExample) |
| CN (1) | CN101959405B (enExample) |
| AU (1) | AU2009221722B2 (enExample) |
| BR (1) | BRPI0910282A2 (enExample) |
| CA (1) | CA2716664C (enExample) |
| DK (1) | DK2262364T3 (enExample) |
| EA (1) | EA018225B1 (enExample) |
| ES (1) | ES2567451T3 (enExample) |
| IL (1) | IL207570A (enExample) |
| MA (1) | MA32175B1 (enExample) |
| MX (1) | MX2010009752A (enExample) |
| NZ (1) | NZ587343A (enExample) |
| WO (1) | WO2009111700A2 (enExample) |
| ZA (1) | ZA201006367B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009221722B2 (en) * | 2008-03-07 | 2014-12-18 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
| EA023430B1 (ru) | 2009-03-30 | 2016-06-30 | виТиви ТЕРАПЬЮТИКС ЭлЭлСи | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| RU2013127611A (ru) | 2010-12-23 | 2015-01-27 | Пфайзер Инк. | Модуляторы глюкагонового рецептора |
| WO2012096824A1 (en) * | 2011-01-12 | 2012-07-19 | Transtech Pharma, Inc. | Phenylglyoxylic acid derivatives and their preparation and use |
| MX2013009140A (es) | 2011-02-08 | 2013-10-01 | Pfizer | Moduladores del receptor de glucagon. |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP2015510947A (ja) * | 2012-03-22 | 2015-04-13 | トランステック・ファーマ，エルエルシー | 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用 |
| IN2015DN03795A (enExample) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
| CN104968341B (zh) | 2013-01-17 | 2020-06-09 | Vtv治疗有限责任公司 | Glp1r激动剂和二甲双胍的组合及其在制备治疗2型糖尿病和其他障碍的药物中的用途 |
| CA2955836C (en) * | 2014-07-25 | 2023-02-14 | Celgene International Ii Sarl | Glp-1 receptor modulators |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| TW201925204A (zh) * | 2017-11-22 | 2019-07-01 | 日商第一三共股份有限公司 | 稠合三環化合物 |
| KR20210005843A (ko) | 2018-05-08 | 2021-01-15 | 브이티브이 테라퓨틱스 엘엘씨 | Glp1r 작용제의 치료적 용도 |
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| WO2020207474A1 (en) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| CN115315426B (zh) | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| EP4130005A4 (en) | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| TW202210461A (zh) * | 2020-05-28 | 2022-03-16 | 中國大陸商杭州中美華東製藥有限公司 | 一種（ｓ）—２—胺基—３—（４—（２，３—二甲基吡啶—４—基）苯基）丙酸甲酯二酸鹽的製備方法 |
| EP4159737A4 (en) * | 2020-05-28 | 2024-10-09 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | METHOD FOR PREPARING A GLP-1 RECEPTOR AGONIST-FREE BASE |
| JP2023539584A (ja) | 2020-09-01 | 2023-09-15 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| US20230382899A1 (en) * | 2020-10-14 | 2023-11-30 | Qilu Regor Therapeutics Inc. | Crystal forms of glp-1r agonists and uses thereof |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CA3200245A1 (en) | 2020-11-27 | 2022-06-02 | Junjun Wu | Benzimidazole derivative and preparation method therefor and medical use thereof |
| CN116940561A (zh) | 2021-03-22 | 2023-10-24 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| EP4317145A4 (en) | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| WO2022262615A1 (zh) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | 蒽类化合物、其制备方法和医药用途 |
| AU2022300055A1 (en) | 2021-06-24 | 2024-01-18 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1 receptor agonist and composition and use thereof |
| CN115521320B (zh) * | 2021-06-25 | 2023-09-05 | 沈阳兴齐眼药股份有限公司 | 一种制备普拉洛芬的方法 |
| WO2024063143A1 (ja) | 2022-09-22 | 2024-03-28 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6345270A (ja) * | 1986-02-11 | 1988-02-26 | Takeda Chem Ind Ltd | １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物 |
| EP0233728A1 (en) | 1986-02-11 | 1987-08-26 | Takeda Chemical Industries, Ltd. | 1,4-Benzoxazine derivatives their production and use |
| EP0873295B1 (en) * | 1995-10-06 | 2003-04-02 | Ligand Pharmaceuticals, Inc. | Dimer-selective rxr modulators and methods for their use |
| EP1147094A1 (en) * | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| WO2001040192A1 (en) * | 1999-12-03 | 2001-06-07 | Kyoto Pharmaceutical Industries, Ltd. | Novel heterocyclic compounds and salts thereof and medicinal use of the same |
| EP1125925A1 (en) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US20050222036A1 (en) | 2000-08-24 | 2005-10-06 | Thomas Jefferson University | Peptide compositions with effects on blood glucose |
| ATE435210T1 (de) * | 2003-03-26 | 2009-07-15 | Actelion Pharmaceuticals Ltd | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten |
| AU2009221722B2 (en) * | 2008-03-07 | 2014-12-18 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
| EP2579888A2 (en) | 2010-06-09 | 2013-04-17 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
-
2009
- 2009-03-06 AU AU2009221722A patent/AU2009221722B2/en active Active
- 2009-03-06 WO PCT/US2009/036333 patent/WO2009111700A2/en not_active Ceased
- 2009-03-06 CA CA2716664A patent/CA2716664C/en active Active
- 2009-03-06 CN CN200980108115.XA patent/CN101959405B/zh active Active
- 2009-03-06 BR BRPI0910282-5A patent/BRPI0910282A2/pt not_active Application Discontinuation
- 2009-03-06 KR KR1020107020688A patent/KR101616737B1/ko not_active Expired - Fee Related
- 2009-03-06 EA EA201071045A patent/EA018225B1/ru not_active IP Right Cessation
- 2009-03-06 DK DK09718287.7T patent/DK2262364T3/en active
- 2009-03-06 NZ NZ587343A patent/NZ587343A/en not_active IP Right Cessation
- 2009-03-06 US US12/399,504 patent/US7727983B2/en active Active
- 2009-03-06 ES ES09718287T patent/ES2567451T3/es active Active
- 2009-03-06 JP JP2010549910A patent/JP5382952B2/ja active Active
- 2009-03-06 MX MX2010009752A patent/MX2010009752A/es active IP Right Grant
- 2009-03-06 EP EP09718287.7A patent/EP2262364B1/en active Active
-
2010
- 2010-04-13 US US12/759,010 patent/US7790714B2/en active Active
- 2010-08-03 US US12/849,225 patent/US7906507B2/en active Active
- 2010-08-12 IL IL207570A patent/IL207570A/en active IP Right Grant
- 2010-08-31 US US12/872,580 patent/US8524708B2/en not_active Expired - Fee Related
- 2010-09-10 ZA ZA2010/06367A patent/ZA201006367B/en unknown
- 2010-09-30 MA MA33212A patent/MA32175B1/fr unknown
-
2013
- 2013-08-01 US US13/956,578 patent/US8703766B2/en not_active Expired - Fee Related
-
2014
- 2014-03-05 US US14/197,771 patent/US8933222B2/en active Active
- 2014-12-01 US US14/556,837 patent/US9120813B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2567451T3 (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes | |
| AR053202A1 (es) | Pirazolpiridinas y analogos de las mismas como inmunomoduladores | |
| PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
| ES2564179T3 (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales | |
| AR049331A1 (es) | Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas. | |
| PE20091883A1 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| ES2381683T3 (es) | Compuestos de espiro-oxindol y sus usos como agentes terapéuticos | |
| AR053710A1 (es) | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos | |
| AR063280A1 (es) | Uso de compuestos de espiro-oxindol como agentes terapeuticos | |
| CY1112006T1 (el) | Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c | |
| ES2452299T3 (es) | Compuestos heterocíclicos fungicidas | |
| EA201390022A8 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ) | |
| AR049104A1 (es) | Pirimidinas como inhibidores de plk, composiciones farmaceuticas que las contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades proliferativas, inflamatorias y autoinmunes. | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| AR053014A1 (es) | Compuestos de pirazol inhibidores de raf quinasa | |
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| CA2434727A1 (en) | Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR069509A1 (es) | Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10 | |
| CO6210701A2 (es) | Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico | |
| CO6140061A2 (es) | Compuestos de pirazol heterobiciclicos y metodos de uso | |
| AR090191A1 (es) | Derivados del acido fenil alcanoico como agonistas gpr | |
| CO6150164A2 (es) | Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas |